Cytoreductive surgery in ovarian cancer: an integrative review/Cirurgia citorredutora no cancer de ovario: uma revisao integrativa
Ovarian cancer ranks fifth on the list of causes of cancer mortality in women. The most used therapeutic approach for this condition is cytoreductive surgery combined with chemotherapy. This review aims to analyze survival related to cytoreductive surgery in cases of ovarian cancer. This occurred th...
Gespeichert in:
Veröffentlicht in: | Revista de medicina (São Paulo, Brazil) Brazil), 2024-11, Vol.103 (6) |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | por |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Ovarian cancer ranks fifth on the list of causes of cancer mortality in women. The most used therapeutic approach for this condition is cytoreductive surgery combined with chemotherapy. This review aims to analyze survival related to cytoreductive surgery in cases of ovarian cancer. This occurred through an integrative review of articles from 2018 to 2022, following the PRISMA criteria, in the PubMed database. In total, 32 articles were found and of these, 18 entered this review. Therefore, cytoreduction followed by platinum/ taxane-based chemotherapy is the current standard treatment for ovarian cancer. Survival outcomes are inversely related to initial and residual tumor burden after surgery. It appears that cytoreductive surgery is a viable technique that has been associated with good patient outcomes, including a median survival rate of 53 months. KEY WORDS: Ovarian Neoplasms; Cytoreductive Surgical Procedures; Chemotherapy, Adjuvants. O cancer de ovario ocupa o quinto lugar na lista de causas de mortalidade por cancer em mulheres. A abordagem terapeutica mais utilizada para essa condicao e a cirurgia citorredutora combinada com quimioterapia. Esta revisao objetiva analisar a sobrevida relacionada a intervencao cirurgica citorredutora em casos de cancer de ovario. Isso ocorreu por meio de uma revisao integrativa com artigos de 2018 a 2022, seguindo os criterios PRISMA, no banco de dados PubMed. Ao total, 32 artigos foram encontrados e desses, 18 adentraram essa revisao. Sendo assim, a citorreducao, seguida de quimioterapia a base de platina/taxano, e o tratamento padrao atual para o cancer de ovario. Os resultados de sobrevida estao inversamente relacionados a carga tumoral inicial e residual apos a cirurgia. Constata-se que a cirurgia citorredutora e uma tecnica viavel que tem sido associada a bons prognosticos aos pacientes, incluindo uma taxa media de sobrevida de 53 meses. PALAVRAS-CHAVE: Cancer do ovario; Carcinoma de ovario; Cirurgia citorredutora; Quimioterapia. |
---|---|
ISSN: | 0034-8554 |
DOI: | 10.11606/issn.1679-9836.v103i6e-224140 |